Biogen (BIIB) to present new late-breaking Litifilimab Phase 2 AMETHYST data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology annual meeting

Biogen's announcement to present late-breaking data on litifilimab for cutaneous lupus erythematosus at a prominent dermatology conference highlights significant advancements in their clinical pipeline.

Newsquawk StaffPublished 19 Mar 2026, 11:52 UTCOn the live feed at 11:32 UTC — 2 more headlines followed before this page went public

Newsquawk headlinesUTC

11:42

JPMorgan’s strategy team has cut its year-end target for the S&P 500 from 7500 to 7200 on the “geopolitical overhang”

11:36

Alibaba (9988 HK / BABA) says over the next five years, our goal is to surpass USD 100bln in combined cloud and AI external revenue

11:32

Biogen (BIIB) to present new late-breaking Litifilimab Phase 2 AMETHYST data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology annual meeting

11:31

Tesla (TSLA) and Ford (F) to produce LFP batteries in the US using Chinese gear, The Information reports

11:30

PBoC Governor Pan meets Hong Kong financial secretary Paul Chan; discusses current macro economy, deepening mainland-Hong Kong financial connectivity, strengthening offshore RMB market and enhancing HK's status as an international financial center

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)
Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designation
CLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement when left untreated, and has no targeted treatment option

Context

The recent FDA Breakthrough Therapy Designation strengthens the drug’s potential and could position Biogen favorably in a market with high unmet needs, impacting investor sentiment and stock performance as expectations build ahead of the meeting.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/26 Aug · 12:56

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

META +2.6%.

EQUITIES/2 Sep · 11:20

Uber (UBER) is said to be cutting 3,300 jobs amid an overall to cut management layers, reports suggest

+2.6%market

EQUITIES/2 Sep · 10:35

Deutsche Telekom (DTE GY) CFO is to leave the Co. in April 2027; has named Mirchandani as new CFO

−0.3%market

EQUITIES/1 Sep · 20:06

Dell (DELL) Q2 2026 (USD): Adj. EPS 7.04 (exp. 4.91), Revenue 47.0bln (exp. 44.9bln)

+10.1%market

EQUITIES/28 Aug · 17:01

US appeals court rejects Kalshi's bid for injunction to block Nevada Gaming regulators' oversight of sports events contracts

+2.7%market

EQUITIES/27 Aug · 14:19

California AG says Paramount (PSKY) settlement is possible, Co. has to follow the rules, via CNBC TV

+2.4%market

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.